Last updated: March 16, 2026
What is the Drug Identified by NDC 62135-0439?
NDC 62135-0439 refers to Xyrem (sodium oxybate), a medication used primarily to treat narcolepsy with cataplexy and excessive daytime sleepiness. It is a central nervous system depressant with a high potential for abuse. The drug is marketed by Jazz Pharmaceuticals.
Market Size and Competition
Current Market Landscape
| Category |
Data |
Source |
| Addressable Population |
Approximately 50,000-70,000 narcolepsy patients in the U.S. |
National Institutes of Health [1] |
| Estimated U.S. Sales (2022) |
$1.2 billion |
IQVIA [2] |
| Main Competitors |
Xyrem (Jazz Pharmaceuticals), generic sodium oxybate (pending or limited) |
U.S. FDA, market reports |
Growth Drivers
- Increasing diagnosis rates: Narcolepsy diagnosis is rising due to improved awareness and diagnostic tools.
- Off-label uses: Emerging evidence suggests potential off-label applications, such as alcohol dependence, which could expand market size.
- Reimbursement policies: Insurance coverage favors adherence, boosting prescriptions.
Risks and Competition
- Generics: Pending FDA approvals for generic sodium oxybate could erode brand-market share.
- Regulatory restrictions: Schedule III classification limits prescribing, impacting market expansion.
- Safety concerns: Abuse potential may lead to regulatory constraints.
Price Dynamics and Projections
Current Pricing
| Metric |
Data |
Source |
| Retail Price (per 30 mL bottle, 500 mg/mL) |
approximately $700 |
GoodRx [3] |
| Average Wholesale Price (AWP) |
$700–$800 |
Red Book [4] |
| Reimbursement |
Typically covers 80% of AWP with insurance |
CMS, private insurers |
Pricing Trends (2020–2022)
- Slight increase driven by inflation and manufacturing costs.
- No significant discounts or rebates publicly reported.
- Price stability maintained due to limited generic competition.
Future Price Projections (Next 3–5 Years)
| Scenario |
Assumptions |
Estimated Price Range |
Time Frame |
Source |
Notes |
| Conservative |
No imminent generic entry, regulatory constraints persist |
$700–$750 |
2023–2025 |
Market analysis |
Price stabilizes with inflationary pressure |
| Moderate |
Generic sodium oxybate approved and launched |
Downward pressure, 20–30% |
2023–2024 |
Industry reports |
Lower retail price, potential market share shift |
| Aggressive |
Regulatory restrictions tighten, reducing prescriptions |
Possible price increase or market contraction |
2023–2025 |
Regulatory analysis |
May hinder access, limit revenue growth |
Price Sensitivity Factors
- Prescription volume growth depends on diagnosis rates and off-label use.
- Price reductions could occur with generics; manufacturers may offer rebates.
- Insurance reimbursement policies influence patient out-of-pocket costs.
Regulatory Environment Impact
- Schedule III classification limits prescribing flexibility.
- FDA surveillance for misuse can lead to restrictions.
- Potential approval of generics could accelerate price declines.
Key Takeaways
- Currently, Xyrem remains a high-value product with stable prices due to limited generic competition.
- Market growth hinges on diagnosis rates, insurance coverage, and regulatory constraints.
- The entry of generics could significantly reduce prices within 1–2 years.
- Price stability is expected if regulatory restrictions and market dynamics remain unchanged.
FAQs
Q1: How soon could generic sodium oxybate enter the market?
A1: FDA approvals for generics are pending; typical timeline is 1–2 years if approved.
Q2: What factors influence the price of Xyrem?
A2: Market demand, regulatory restrictions, manufacturing costs, and competition from generics.
Q3: How does insurance coverage affect pricing?
A3: Insurance often covers most of the drug cost, minimizing out-of-pocket expenses and stabilizing retail prices.
Q4: Are there opportunities for alternative therapies?
A4: Some research is exploring new agents for narcolepsy, but none currently surpass Xyrem’s market share.
Q5: What is the potential impact of regulatory actions on prices?
A5: Stricter controls can limit prescriptions, potentially reducing revenues or increasing prices if supply tightens.
References
[1] National Institute of Neurological Disorders and Stroke. (2022). Narcolepsy fact sheet.
[2] IQVIA. (2022). U.S. Prescription Drug Market Data.
[3] GoodRx. (2023). Cost of Xyrem.
[4] Red Book. (2022). Wholesale drug pricing.
